Pathstone Holdings
REGN icon

Pathstone Holdings’s Regeneron Pharmaceuticals REGN Stock Holding History

Pathstone Holdings’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.65M Sell
13,825
-2,087
-13% -$1.42M 0.03% 460
2026
Q1 		$12.3M Buy
15,912
+988
+7% +$756K 0.05% 279
2025
Q4 		$11.5M Buy
14,924
+2,284
+18% +$1.55M 0.04% 296
2025
Q3 		$7.11M Buy
12,640
+2,097
+20% +$1.19M 0.03% 453
2025
Q2 		$5.53M Sell
10,543
-8,595
-45% -$4.8M 0.02% 509
2025
Q1 		$12.1M Buy
19,138
+5,461
+40% +$3.76M 0.05% 273
2024
Q4 		$9.74M Sell
13,677
-1,254
-8% -$1.05M 0.04% 323
2024
Q3 		$15.7M Buy
14,931
+65
+0.4% +$72.3K 0.07% 209
2024
Q2 		$15.6M Buy
14,866
+40
+0.3% +$38.8K 0.07% 203
2024
Q1 		$14.3M Buy
14,826
+4,419
+42% +$4.2M 0.07% 215
2023
Q4 		$9.18M Buy
+10,407
New +$8.57M 0.05% 273

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Pathstone Holdings's REGN Position: Q2 2026 in Review

Pathstone Holdings reduced its Regeneron Pharmaceuticals (REGN) stake by 13% in Q2 2026, selling an estimated $1.42M and leaving 13,825 shares worth $8.65M. The position accounts for 0.03% of the portfolio, ranked #460.

Pathstone Holdings first reported a position in REGN in Q4 2023 and has held it in 11 quarters since. The position peaked at $15.7M in Q3 2024. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Pathstone Holdings held 13,825 shares of Regeneron Pharmaceuticals worth $8.65M as of Q2 2026.
  • Pathstone Holdings sold 2,087 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $1.42M.
  • Regeneron Pharmaceuticals made up 0.03% of Pathstone Holdings's portfolio in Q2 2026, its #460 holding.
  • Pathstone Holdings first reported a position in Regeneron Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • Pathstone Holdings's Regeneron Pharmaceuticals position peaked at $15.7M in Q3 2024.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Pathstone Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.